Clinical TrialsSearch results
Number of results: 598
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Completed
- A prospective clinical trial to evaluate the efficacy and safety of 7-mm-diamter covered biliary metal stent
- Pancreatic cancer
- Ishiwatari Hirotoshi
- 2020-11-16
Completed
- A phase II trial of TAS-102 in combination with cetuximab for metastatic colorectal cancer patients
- Metastatic RAS wild type colorectal cancer with refractory or intolerable to standard chemotherapy
- Izawa Naoki
- 2019-03-29
Completed
- A phase II study of osimertinib in patients with poor performance status and non-small-cell lung cancer
- EGFR mutation T790M-positive non-small-cell lung cancer
- Murakami Haruyasu
- 2019-03-12
Completed
- A phase II study of gemcitabine and nab-paclitaxel followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancer
- Locally advanced pancreatic cancer
- Sudo Kentaro
- 2019-03-11
Completed
- A phase II study of gefitinib with TRT in patients with stage III NSCLC harboring EGFR mutations
- Non-Small Cell Lung Cancer
- Murakami Haruyasu
- 2019-03-11
Completed
- A Phase I study of irinotecan, bevacizumab and TAS-102 for metastatic colorectal cancer patients
- unresectable metastatic colorectal cancer
- Yamazaki Kentaro
- 2019-01-22
Completed
- A phase I study of chemoradiotherapy using CBDCA + nab-PTX for elderly stage III NSCLC
- Clinical stage III non-small-cell lung cancer
- Takahashi Toshiaki
- 2019-03-11
Completed
- A phase 2 study of afatinib for NSCLC with uncommon EGFR mutation detected by NGS
- Non-small cell lung cancer with uncommon EGFR mutaiton
- Takahashi Toshiaki
- 2019-05-20
No Longer Recruiting
- Crutches Walking independence factor
- Fracture of lower limb,Meniscus tear,Knee ligament injury,Achilles tendon rupture
- Yamashita Teruaki
- 2022-06-11
No Longer Recruiting
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants with Advanced Cancers
- Neoplasms
- Fujikawa Ei
- 2023-01-31